Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
GnRH antagonist |
| gptkbp:alternativeName |
gptkb:Relugolix
|
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:Japan
gptkb:United_States |
| gptkbp:ATCCode |
L02BX13
|
| gptkbp:brand |
gptkb:Orgovyx
|
| gptkbp:CASNumber |
737789-87-6
|
| gptkbp:chemicalFormula |
C29H27F2N7O5
|
| gptkbp:clinicalTrialPhase |
Phase III (as of 2023)
|
| gptkbp:developedBy |
gptkb:Takeda_Pharmaceutical_Company
|
| gptkbp:effect |
reduces follicle-stimulating hormone
reduces luteinizing hormone |
| https://www.w3.org/2000/01/rdf-schema#label |
TAK-385
|
| gptkbp:indication |
advanced prostate cancer
|
| gptkbp:intendedUse |
treatment of prostate cancer
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
suppresses testosterone production
|
| gptkbp:molecularWeight |
627.6 g/mol
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
fatigue increased liver enzymes musculoskeletal pain hot flush |
| gptkbp:target |
gonadotropin-releasing hormone receptor
|
| gptkbp:bfsParent |
gptkb:Orgovyx
|
| gptkbp:bfsLayer |
7
|